Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Biotechnology

Healthcare
$119.04 +3.57%

+$3.42 today

Market cap
$8.25B
Beta
1.92
P/E (TTM)
-33.3
EPS (TTM)
-$2.98
52W Low $60.80High $122.20

Volume 2.01M

Average 0.81M

RYTM Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation dips below year-ago levels

Q3 FY2026 stock-based compensation of $1.93M fell 89.8% year over year, behind the +60.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 96.1% from the prior quarter. Over 3 fiscal years it compounded at +49.9% a year.

Context

  • Stock-based compensation amounted to 35.2% of revenue in FY2025, up 4.7 pp from a year earlier.
  • Stock-based compensation increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -89.8% toward the trailing-twelve-month pace of +60.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.93M-96.1% QoQ
Last fiscal yearDec 2025
$66.82M+68.4% YoY
LTMSep 2026
$93.45M+60.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-89.8%——
1 year+68.4%——
3-year CAGR+49.9%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
66.82M USD
Year-over-year change
+68.4%
4-year CAGR
+33.9%

Stock-Based Compensation vs competitors

How RYTM compares with its peers on the latest reported figures

  • RYTM's LTM Sep 2026 stock-based compensation of $93.45M is the 2nd largest of the 11 companies compared; the peer median is $19.98M.
  • Its year-over-year change of +60.8% is the 7th highest of 11, against a peer median of +97.8%.
  • Stock-based compensation amounts to 33.3% of revenue for RYTM, versus a peer median of 20.4%.
RYTM Competitors Peer median
Stock-Based Compensation for RYTM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$172.73B +92559.3%-2.6%16.8%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$93.45M +60.8%+49.9%33.3%
GPCRStructure Therapeutics Inc.LTM Jun 2026$51.48M +103.6%+125.9%—
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$41.75M +456.0%+204.9%—
VKTXViking Therapeutics, Inc.LTM Jun 2026$37.39M -5.4%+67.6%—
MAZEMaze Therapeutics, Inc.LTM Mar 2026$20.28M +92.0%+34.5%101.4%
SEPNSepterna, Inc.LTM Sep 2026$19.67M +177.6%+77.3%20.4%
BIOABioAge Labs, Inc.LTM Mar 2026$13M +43.2%+66.3%126.0%
BMEABiomea Fusion, Inc.LTM Mar 2026$4.16M -75.9%-2.7%—
PTNPalatin Technologies, Inc.LTM Mar 2026$1.24M -22.2%-18.0%9.6%
BLTEBelite Bio, IncLTM Jun 2026$45.7K +408.5%+197.2%—
Peer median (excluding RYTM) $19.98M+97.8%+67.0%20.4%

Competitors are the stored peer set for RYTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(69.61M)(181.12M)(184.68M)(260.6M)(196.54M)
Depreciation & Amortization1.16M1.67M1.76M1.56M1.34M
Deferred Income Tax(100M)0000
Stock-Based Compensation20.8M19.83M32.55M39.68M66.82M
Change in Working Capital1.9M(19.72M)4.81M10.58M(968K)
Accounts Receivables(1.25M)(5.2M)(8.64M)(3.65M)(7.57M)
Inventory(11K)(2.81M)(5.71M)(10.12M)(7.47M)
Accounts Payables18.31M1.54M14.77M21.92M21.89M
Other Working Capital(15.15M)(13.26M)4.38M2.42M(7.82M)
Other Non-Cash Items(250K)5.91M9.4M94.9M13.68M
Operating Cash Flow(146M)(173.43M)(136.16M)(113.88M)(115.68M)
Capital Expenditures(5.43M)(4.28M)(47K)0(953K)
Acquisitions (Net)100M4M000
Purchases of Investments(524.97M)(251.94M)(354.92M)(268.31M)(348.67M)
Sales of Investments361.25M284.25M354.97M260.64M252.47M
Other Investing Activities7M(4M)(5.67M)(40.5M)(40M)
Investing Cash Flow(62.16M)28.03M(5.67M)(48.17M)(137.15M)
Debt Repayment000(12.9M)0
Common Stock Issued161.73M131.11M48.88M195.24M237.88M
Common Stock Repurchased00000
Dividends Paid000(3.97M)0
Other Financing Activities4.76M82.72M25.49M12.87M(19.92M)
Financing Cash Flow166.48M213.83M74.37M191.24M217.96M
Effect of Forex Changes00(142K)2K87K
Net Change in Cash(41.68M)68.43M(67.6M)29.19M(34.78M)
Free Cash Flow(151.44M)(177.71M)(136.2M)(113.88M)(116.63M)

Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Intrinsic Alpha fair value

Locked

Current Price

$119.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.